Management of Advanced Stage Hodgkin Lymphoma

Authors:
Ranjana Advani From Stanford University Medical Center, Stanford, California.

Search for other papers by Ranjana Advani in
Current site
Google Scholar
PubMed Close
 MD
,
Weiyun Z. Ai From Stanford University Medical Center, Stanford, California.

Search for other papers by Weiyun Z. Ai in
Current site
Google Scholar
PubMed Close
 MD, PhD
, and
Sandra J. Horning From Stanford University Medical Center, Stanford, California.

Search for other papers by Sandra J. Horning in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 4: Issue 3
Online Publication Date:
Mar 2006
DOI:
https://doi.org/10.6004/jnccn.2006.0023
Full access

Although advanced Hodgkin lymphoma is highly curable, balancing the high cure rate with long-term toxicity is challenging. ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) is the standard chemotherapy regimen, producing a high cure rate with acceptable toxicity. Stanford V and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) are new regimens with encouraging results and are undergoing randomized clinical trials. The International Prognostic Score provides a clinical tool that may help identify patients with high-risk disease who may require a more aggressive regimen. Consolidative radiation's role in managing advanced Hodgkin lymphoma is still controversial, but it is most accepted for bulky or residual disease or after brief chemotherapy. The development and integration of newer imaging tools, such as fluorodeoxyglucose–positron emission tomography imaging, may allow a more precise evaluation of disease and help define which patients might benefit from consolidative treatment.

Correspondence: Ranjana Advani, MD, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305. E-mail: radvani@stanford.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Longo D, Young R, Wesley M et al.. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295–1306.

  • 2.

    DeVita VT Jr, Simon RM, Hubbard SM et al.. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587–595.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Vose J, Bierman P, Anderson J et al.. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. J Clin Oncol 1991;9:1421–1425.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Harding MJ, McNulty LJ, Paul J et al.. Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease. Eur J Cancer 1991;27:1002–1006.

  • 5.

    Hancock BW, Vaughan Hudson G, Vaughan Hudson B et al.. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease—long term results. Br J Cancer 1991;63:579–582.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Bonadonna G, Zucali R, Monfardini S et al.. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252–259.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Canellos GP, Anderson JR, Propert KJ et al.. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.

  • 8.

    Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417–1418.

  • 9.

    Viviani S, Bonadonna G, Santoro A et al.. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:1421–1430.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Glick JH, Young ML, Harrington D et al.. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998;16:19–26.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Duggan DB, Petroni GR, Johnson JL et al.. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607–614.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Viviani S, Santoro A, Ragni G et al.. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985;21:601–605.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Horning SJ, Hoppe RT, Breslin S et al.. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630–637.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Horning SJ, Hoppe R, Advani R et al.. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients [abstract]. Blood 2004;104 Abstract 308.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Yahalom J, Edwards-Bennet S, Jacobs J et al.. Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): the Memorial Sloan-Kettering Cancer Center (MSKCC) experience [abstract]. Blood 2003 Abstract 1459.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Horning SJ, Williams J, Bartlett NL et al.. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol 2000;18:972–980.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Aversa SM, Salvagno L, Soraru M et al.. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol 2004;112:141–147.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Johnson P, Hoskin P, Horwich A et al.. Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): results of a UK NCRI/LTO randomised phase II trial [abstract]. Blood 2004;104 Abstract 311.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Gobbi PG, Levis A, Chisesi T et al.. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198–9207.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1996;7[suppl 4]:95–98.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Diehl V, Franklin J, Pfreundschuh M et al.. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386–2395.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Connors JM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400–6408.

  • 24.

    Diehl V, Brillant C, Franklin J et al.. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12-trials of the German Hodgkin Study Group (GHSG) [abstract]. Blood 2004;104 Abstract 307.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Sieber M, Bredenfeld H, Josting A et al.. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:1734–1739.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Markova J, Zidka M, Kozak T. Osteonecrosis as a complication of treating Hodgkin's lymphoma after BEACOPP chemotherapy. Ann Oncol 2005;16(Suppl 5). Abstract 269.

  • 27.

    Federico M, Bellei M, Brice P et al.. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003;21:2320–2325.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Proctor SJ, Mackie M, Dawson A et al.. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002;38:795–806.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Young RC, Canellos GP, Chabner BA et al.. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978;42:1001–1007.

  • 30.

    Loeffler M, Brosteanu O, Hasenclever D et al.. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998;16:818–829.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Ferme C, Sebban C, Hennequin C et al.. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 2000;95:2246–2252.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Hancock SL, Hoppe RT, Horning SJ et al.. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 1988;109:183–189.

  • 33.

    Aleman BM, Raemaekers JM, Tirelli U et al.. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396–2406.

  • 34.

    Laskar S, Gupta T, Vimal S et al.. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62–68.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Friedberg JW, Fischman A, Neuberg D et al.. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85–92.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Wirth A, Seymour JF, Hicks RJ et al.. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262–268.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Naumann R, Beuthien-Baumann B, Reiss A et al.. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620–625.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Spaepen K, Stroobants S, Dupont P et al.. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272–278.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Jerusalem G, Beguin Y, Fassotte MF et al.. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123–130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Weihrauch MR, Re D, Scheidhauer K et al.. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930–2934.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2006 by the National Comprehensive Cancer Network
Page Numbers:
7
Article Category:
Research Article
Received:
18 Oct 2005
Accepted:
07 Dec 2005
Print Publication Date:
01 Mar 2006
Online Publication Date:
Mar 2006
Keywords:
Prognostic factors; risk-adapted therapy; Hodgkin lymphoma

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 645 419 56
PDF Downloads 331 172 16
EPUB Downloads 0 0 0